期刊文献+

阳离子交换树脂——HPLC法测定伊立替康脂质体包封率 被引量:2

Determination of the Entrapment Efficiency of Irinotecan liposomes by cation Exchange resin-HPLC
下载PDF
导出
摘要 目的建立一种简单有效的伊立替康脂质体包封率测定方法。方法以阳离子交换树脂法分离游离的伊立替康和脂质体,HPLC法测定脂质体中伊立替康的含量,岛津c18(4.6×250mm,5μm,pH为40的甲醇-乙腈-磷酸盐缓冲液(55:5:45,加入三乙胺10mL,磷酸调节pH)为流动相,流速为1.0mL/min.检测波长为254nm,测定包封率。结果阳离子交换树脂对溶液中伊立替康的吸附率达到100%,对空白脂质体和伊立替康物理混合物的中的伊立替康吸附率达到100%。在01—20μg/mL范围内含量测定方法的线性关系良好,精密度RSD小于1.3%,平均回收率为99.87%。结论采用阳离子交换树脂-HPLC方法用于分离、测定脂质体包封率准确可靠、简便可行、重现性好,符合制剂的分析要求。 Abstact: Objective To establish cation exchange resin-HPLC method for the determination of the entrapment efficiency of Irinotecan liposomes. Methods The free Irinotecan from the liposomes separated by Cation exchange resin. The entrapment efficiency of Irinotecan liposomes was determined by HPLC. HPLC conditions were as follows: C18 column (4.6×250mm, 5μm), the mobile phase consisted of methanol-acetonitrilephosphate (55:5:45) added triethylamine 10 mL(pH 4.0), the flow rate 1.0mL/min, the detection wavelength 254 nm. Resμt By flowing through the cation exchange resin,Irinotecan in solution was absorbed completely, in the mixture of blank liposomes and Irinotecan, Irinotecan was absorbed completely too. The calibration curve was liner (r=0.999 8) with the range of 0.1-20μg/mL for Irinotecan. The precision RSD was less than 1.3%. The average recovery of Irinotecan with blank liposomes was 99.87%. Conclusion The method used to separate and determine the entrapment efficiency of Irinotecan was feasible, quick, accurate and efficiency. Key words: liposomes; entrapment efficiency; cation exchange resin; Irinotecan
出处 《现代中药研究与实践》 CAS 2012年第6期41-44,共4页 Research and Practice on Chinese Medicines
关键词 脂质体 包封率 阳离子交换树脂 伊立替康 liposomes entrapment efficiency cation exchange resin Irinotecan
  • 相关文献

参考文献3

二级参考文献13

  • 1李唐棣,郝丽梅,梅兴国.脂质体包封率的研究进展[J].国外医学(药学分册),2006,33(3):224-227. 被引量:28
  • 2涂雪琼,李红,张彧.司帕沙星滴眼液的制备及稳定性考察[J].中国药业,2006,15(9):47-48. 被引量:2
  • 3甘勇,林艳琼,陈庆华.眼用微粒给药系统的研究进展[J].中国药学杂志,2006,41(13):967-970. 被引量:10
  • 4李宝齐,邓英杰,杨静文.超滤-HPLC法测定盐酸拓扑替康脂质体包封率[J].中国新药杂志,2007,16(1):58-61. 被引量:15
  • 5EL-RIDY M S, MOSTAFA D M,SHEHAB A,et al. Biological Evaluation of phyrazinamide liposomes for freatment of mycobacterium tuberculosis [ J ]. Inter J Pharm,2007,330 ( 1-2 ) :82-88.
  • 6SHULAMITH D, ALBERTO G, YECHEZKEL B. Separation of liposome-associated doxorubicin from non-liposome-associated doxorubicin in human plasma: Implications for pharmacokinetic studies [ J ]. Biochim Biophys Acta, 1989, 980 ( 3 ) :381-384.
  • 7Ch. P 2005 Vol Ⅱ (中国药典2005年版二部)[S].2005:162.
  • 8Nicola F. Smith, William D, Figg Alex Sparreboom. Pharmacogenetics of irinotecan metabolism and transport : An update. Toxicol in Vitro, 2006 ( 20 ) : 163.
  • 9PINGQi-neng(平其能).Modem Phannaceutics(现代药剂学),Beijing(北京):ChinaMedico-Pharmaceutical Scienceand Technology Publishing House(中国医药科技出版社),1998.608.
  • 10Gregor lad, Is G. Liposome Technology Volume I, Liposome Preparation and Related Techniques. Second edition. London, England: CRC press, 1993:585.

共引文献24

同被引文献49

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部